NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 03/30/2020 12:52
Last Report Issued 12/17/2014 05:56

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 3042SP
Patient ID 3042SP
Chain 13000800
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 13000800

Received 02/18/2013 11:48

Sample ID 13000800-001
Matrix Serum or Plasma
Patient Name 3042SP
Patient ID 3042SP
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
3042SP Metolazone, Serum/Plasma				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Metolazone	None Detected	ng/mL	5.0	
Synonym(s): Mykrox®; Zaroxolyn®				
Peak blood concentrations averaged 70 ng/mL following a single 7.5 mg oral dose of metolazone in 6 healthy subjects. The blood to plasma ratio for metolazone is approximately 0.8 to 1.				

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.